PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. - Wikidata - awgldk - TriplyDB

PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.

PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.

http://www.wikidata.org/entity/Q46635617

about

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status Down-regulation of LRRK2 in control and DAT transfected HEK cells increases manganese-induced oxidative stress and cell toxicity Functional neuroimaging in Parkinson's disease Manganism in the 21st century: the Hanninen lecture Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers The role of biomarkers and imaging in Parkinson's disease.Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.Neuroimaging in pre-motor Parkinson's disease Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease Neuroimaging: current role in detecting pre-motor Parkinson's disease.Defining at-risk populations for Parkinson's disease: lessons from ongoing studies.Dopaminergic neuronal loss and dopamine-dependent locomotor defects in Fbxo7-deficient zebrafish.Genetics of Parkinson's disease: LRRK2 on the rise.Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake.Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis The nature of progression in Parkinson's disease: an application of non-linear, multivariate, longitudinal random effects modelling.Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function.DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment.LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function Molecular imaging in hereditary forms of parkinsonism.Genetics of Parkinson disease.Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.Normal dopaminergic nigrostriatal innervation in SPG3A hereditary spastic paraplegia.LRRK2 in Parkinson's disease: genetic and clinical studies from patients.Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease.Does uncoupling protein 2 expression qualify as marker of disease status in LRRK2-associated Parkinson's disease?Imaging dopamine transporters in Parkinson's disease.Milestones in neuroimaging.The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.Positron emission tomography neuroimaging in Parkinson's disease.

P2860

Q22254785-27B43211-397C-4C04-8B72-83FD1650B9C1 Q24300605-45A51CDD-5284-41D8-91AC-FBA329870785 Q24339471-D7DDB4FE-5C77-4C48-B687-89E8060695E5 Q27013767-AE1E1CB1-88D4-4399-B2B8-25CF516060B9 Q27015750-FF11DB08-C77F-49B1-8998-7AE9488EB698 Q28589899-B94187BF-12D5-44E1-8D43-718883D6BCE5 Q30525550-E991149B-1348-4F7F-8D2E-990DB533689B Q31041660-87ACA414-7620-47C8-9C6F-DB4EA1643834 Q31158920-1EF2F305-A72A-487E-9554-70E0A6ADA0BF Q33668068-13CF90AD-3A34-4D27-B35A-2559D260D420 Q33676222-2E91993E-ED70-4669-9793-0832A1085581 Q33812599-3F300397-AF22-4B0B-BDB3-9313F4186218 Q34234625-C500A3DE-2509-42AB-A157-C89E96737B41 Q34234632-33D3FA78-BED5-4ED3-84ED-4E6D76DA3C8F Q34469890-A8EA7C22-A62F-4EE9-8908-39DE5B3AD97D Q34470633-B0860D8E-2950-4B4B-ABA3-A36A22B79DF2 Q34540567-380FE8FD-D3B8-48A8-9858-B8A976C72D13 Q34553777-CE743CDD-1BFF-4AD1-9EDD-887EF1654B6C Q34919409-19090B70-1DD5-41FF-8D60-44A4BAA0FEED Q35034718-310CAED6-9097-4690-B62F-DFF9D8E94A97 Q35106295-D1487BDB-F37E-4207-BE7B-AAB9293E794E Q35148581-CECFF916-C2D0-4094-984B-10A5484FBFA4 Q35235888-F8529CEF-362D-40D5-9DFF-1A8856B2FD3C Q35614156-E370AC25-1FED-42D9-A8CB-8364294FB1A9 Q35757332-11ACC148-26CC-4AD3-AEB5-B89DE930997B Q36345908-09C2ED25-44A1-4006-B29A-3827A8A34EFB Q36553302-39475138-18FA-4CDA-BCDA-CB5F51AA6730 Q36581417-67BB6524-7704-4F10-B3E7-126796C668B5 Q36771898-B71769DF-4199-47BE-8460-D84D7226F5A2 Q37037053-C378881E-97E8-41BD-8DFE-398FD58405AB Q37243261-0598AC81-BC86-4580-92FE-131C90A09207 Q37313530-B9155136-7131-4696-9629-80412425E730 Q37344742-BD3484D0-3863-45D7-A50A-ADEA5DC37FB3 Q37608624-FE918514-6524-40B9-990B-E1D48E1F26F8 Q37679384-3792C213-EAF1-4E9D-9263-C63CD59A8D3A Q37712626-70DEB395-2878-4BD7-B69E-23AE96E7A0F7 Q37800096-DFC206B6-37BE-42C2-8F75-FF7AB1DD6895 Q37882576-FD250DB4-1D01-42B5-BDC6-B05D3562C250 Q37910636-0F78F4D5-5BC8-4E6E-A1B0-D64ACF08449A Q37929598-EC2FF57D-D353-4831-843C-A60E8C6890D8

P2860

PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.

http://www.wikidata.org/entity/Q46635617

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

PET in LRRK2 mutations: compar ...... r presymptomatic compensation.

@en

PET in LRRK2 mutations: compar ...... r presymptomatic compensation.

@nl

type

label

PET in LRRK2 mutations: compar ...... r presymptomatic compensation.

@en

PET in LRRK2 mutations: compar ...... r presymptomatic compensation.

@nl

prefLabel

PET in LRRK2 mutations: compar ...... r presymptomatic compensation.

@en

PET in LRRK2 mutations: compar ...... r presymptomatic compensation.

@nl

P1433

Q46635617-D22D9D74-BBF8-4848-980C-DEF1BE656F8A

P1476

Q46635617-08D8C668-8779-476B-A10A-59B0BF6EE290

P2093

Q46635617-34F53D40-92A4-4429-A772-DD82C83DCBAC

Q46635617-3A35A3F4-3112-443E-AEBB-2770A526E94C

Q46635617-3E84102E-7549-4ED4-A4ED-D27C11E02D2D

Q46635617-3F3CF79F-7E39-4CA7-B8CC-6DDC2EA1E331

Q46635617-41EFD267-EEFC-44C9-8DE4-013E05E4B919

Q46635617-8840DA20-F6C3-42D6-B039-15A94C406D30

Q46635617-BCBBEF06-2FDB-44C7-B1D3-52D5DB24CD2A

Q46635617-DA499C59-9DC4-440E-87CF-4CB03E15C3B8

Q46635617-F57F6A43-287F-4362-BC2B-CE4DEF8CAD86

P2860

Q46635617-08C045CD-9B39-48F4-A745-B655589E99A3

Q46635617-246FF61D-F959-4053-B91E-EA0079C51E4F

Q46635617-267BA824-7A37-4D4B-B826-DD5959560ECD

Q46635617-2910573D-A218-4216-B7B6-1EB4BE77DA43

Q46635617-3BBE99DF-C1E7-4A33-89E9-44AE1A2875E6

Q46635617-3E50BA5F-FEE2-4FC3-A9AE-6FDCFA93DA05

Q46635617-406AD207-E77F-4071-9FF4-78FC270F3E36

Q46635617-43D79694-C291-47BD-ADFE-6CFDD09AAE1A

Q46635617-4425F5AF-BFBB-4632-B69A-94D50B50B0A9

Q46635617-4776639D-DB31-4E3C-9017-D7A5FE23508C

P304

Q46635617-6E3BE0CD-21A1-4D1F-B784-6A7E84636816

P31

Q46635617-D1406AD9-7419-45AE-BC3B-AC3C6C039213

P356

Q46635617-F3751B85-9E21-4DE1-9C75-A660CE23993D

P407

Q46635617-94347851-5B83-4324-813F-36E106435269

P433

Q46635617-39AF1A89-48C1-4761-A3E5-FFB5B216FDEF

P478

Q46635617-A7A616DC-91A3-49E4-A5A1-AE2FCD409D34

P50

Q46635617-3933C722-F7F8-47FF-8F6B-C7D95F09FEA1

Q46635617-64E6CB3F-5937-445D-980F-F2229D625D81

Q46635617-78747800-9104-48C1-9359-B58678A46864

Q46635617-8D3A0D70-0A86-4E81-92B1-41DE4B449BC2

Q46635617-D029143D-A856-473F-B00D-B395BF63216F

Q46635617-F60B3245-FB92-4614-9505-9E3E167959AA

P577

Q46635617-9ED0C6F7-2FDF-48DA-93B0-8364DD81DDC8

P5875

Q46635617-BB251668-4123-4F32-8CC0-8C707F3AD4BA

P698

Q46635617-3E5A9EA6-8002-446A-85DD-7FD0AB7EDB67

P921

Q46635617-A26C3273-59FB-4BBA-A1DA-CF7F51CB905F

P356

P1433

P1476

PET in LRRK2 mutations: compar ...... r presymptomatic compensation.

@en

P2093

A Jon Stoessl

http://www.w3.org/2001/XMLSchema#string

Audrey Strongosky

http://www.w3.org/2001/XMLSchema#string

Chong S Lee

http://www.w3.org/2001/XMLSchema#string

Edwin Mak

http://www.w3.org/2001/XMLSchema#string

Hinke van Netten

http://www.w3.org/2001/XMLSchema#string

Jessamyn Mckenzie

http://www.w3.org/2001/XMLSchema#string

John R Adams

http://www.w3.org/2001/XMLSchema#string

Michael Schulzer

http://www.w3.org/2001/XMLSchema#string

Thomas J Ruth

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations

A large kindred with autosomal dominant Parkinson's disease

A common LRRK2 mutation in idiopathic Parkinson's disease

Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease

Ageing and Parkinson's disease: substantia nigra regional selectivity

The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval.

Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.

Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study.

Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific.

P304

2777-2785

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/AWH607

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 12

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P50

Matthew J. Farrer

Donald Brian Calne

Zbigniew K Wszolek

P577

2005-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7679540

http://www.w3.org/2001/XMLSchema#string

P698

16081470

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease